인쇄하기
취소
|
The 3rd quarter year-to-date (YTD) financial results for KSE-listed pharmaceutical firms, with their fiscal year ending March 2005, collectively show over 12 percent growth in revenue, propelled by aggressive marketing promotions on the leading products in the market.
According to an analysis conducted by the Yakup Shinmoon, the total revenue for these firms through three quarters is 7...